业务进展情况 生命科学解决方案板块2025年利润同比增长7.6%，成为核心增长引擎，而分析仪器板块利润同比下滑 11.2%。 来源：经济观察网 经济观察网 赛默飞世尔（TMO）未来值得关注的事件。 公司业绩目标 管理层在2025年财报中发布2026年全年指引，预计收入同比增长3.9%至5.9%，调整后每股收益（EPS） 增长5.9%至8.4%，并重申长期有机收入增长目标为3%-6%。这一指引将作为评估公司年度表现的关键 基准。 战略推进 2025年公司完成对Solventum过滤与分离业务的收购，并收购赛诺菲新泽西州无菌灌装设施；2025年第 四季度宣布拟以89亿美元收购临床数据服务商Clario，该交易旨在加强生物生产与药品本土化能力。市 场将关注这些并购的协同效应及后续整合效果。 公司持续推出新技术产品（如Orbitrap Astral质谱仪），并与Open AI、陈・扎克伯格研究所等达成合 作，推动人工智能在运营中的应用。 行业状况 招银国际报告指出，2025年制药与生物技术客户需求呈现反弹（第四季度收入高单位数增长），且生物 技术融资恢复可能在未来6-12个月转化为订单增量。该趋势可能成为收入增长的潜 ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $4.2 million, a 37% increase from $3.1 million in Q1 2024, primarily driven by higher instrument consumable and service revenue [23] - Gross profit for Q1 2025 was $2.1 million, representing a gross margin of 49%, compared to $1.4 million and 44% in Q1 2024 [25] - Net loss for Q1 2025 was $19.9 million, compared to $20.7 million in Q1 2024 [27] - Free cash flow loss was approximately $12.1 million for Q1 2025, with expectations of a full-year loss in the range of $40 million to $45 million [27][28] Business Line Data and Key Metrics Changes - Product revenue for Q1 2025 was $2.9 million, including $5,000 from related party revenue, consisting of sales of proteograph instruments and consumable kits [23] - Service revenue for Q1 2025 was $1.2 million, primarily from STACK service projects, indicating strong customer interest [24] - Other revenue was $60,000 for Q1 2025, consisting of lease and shipping revenue [25] Market Data and Key Metrics Changes - Approximately 30% of total revenue comes from academic and government entities, with expectations of weakening in these segments for 2025 [30][42] - The company has not seen direct effects on its supply chain from recent tariffs, as key suppliers manufacture products in the U.S. [31] Company Strategy and Development Direction - The company aims to focus on four key growth drivers in 2025: expanding the user base, driving larger cohort studies, continuing product innovation, and enabling customers to generate actionable biological insights [34] - The partnership with Thermo Fisher Scientific to co-market the Proteograph product suite alongside their Orbitrap Astro Mass Spectrometer is expected to enhance commercial reach [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term vision despite near-term macroeconomic volatility, including tariffs and government funding challenges [6][7] - The company reiterated its full-year 2025 revenue guidance of $17 million to $18 million, representing 24% year-over-year growth at the midpoint [7][29] - Management noted that while there is cautious optimism, the macroeconomic environment remains uncertain, particularly regarding NIH funding and potential tariffs affecting customers [30][45] Other Important Information - The company ended Q1 2025 with approximately $285 million in cash, cash equivalents, and investments, which is seen as a key differentiator in the current environment [8][28] - The company continues its share repurchase program, believing there is a significant dislocation between its core value proposition and stock price [8][27] Q&A Session Summary Question: Can you walk us through the magnitude of the Discovery Life Sciences project? - The project involves a 10,000 sample study aimed at understanding potential biomarker signatures, expected to take 12 to 18 months [36][38] Question: What are the updated expectations for U.S. academic and government customers? - Academic and government customers represent about 30% of revenue, with expectations of weakening in 2025, but Q1 showed stability in revenue and instrument placement [42][44]